Investigating the Role of Viral Hepatitis in the Development of Hepatocellular Carcinoma and the Dependence of Pathogenesis on Viral Hepatitis Types
PDF

Keywords

Hepatocellular carcinoma; Hepatic oncogenesis; Hepatitis B virus; Hepatitis C virus; Hepatitis Delta superinfection; Tumor microenvironment; Oncogenic latency.

How to Cite

Toshpulatova, L. (2026). Investigating the Role of Viral Hepatitis in the Development of Hepatocellular Carcinoma and the Dependence of Pathogenesis on Viral Hepatitis Types. KLINIK VA FUNDAMENTAL TIBBIYOT TADQIQOTLARI JURNALI, 1(5), 79-88. https://innopublication.com/index.php/jcmfr/article/view/602

Abstract

Viral hepatotropic infections remain the predominant drivers of hepatic oncogenesis globally, dictating diverse molecular pathways that fundamentally alter the clinical presentation and progression of hepatocellular carcinoma. This retrospective cohort study evaluates the specific oncogenic impact, latency periods, and morphological tumor characteristics associated with Hepatitis B, Hepatitis C, and Hepatitis D viral infections. By analyzing a strictly defined cohort of 486 patients diagnosed with primary liver malignancy between 2018 and 2024, the investigation quantifies the distinct evolutionary timelines from chronic viral persistence to malignant transformation. Clinical data, including viral load, fibrotic staging via transient elastography, multiphasic computed tomography morphometrics, and serum alpha-fetoprotein concentrations, were synthesized using multivariate regression models. The analysis revealed profound etiological divergence in oncogenic latency. Patients with chronic Hepatitis C virus exhibited a delayed age of tumor onset (63.4 ± 5.8 years) but demonstrated an accelerated transition from established cirrhosis to carcinoma (4.2 ± 1.1 years). Conversely, Hepatitis B virus cohorts presented with malignancies nearly a decade earlier (54.1 ± 6.2 years), frequently bypassing the intermediate cirrhotic phase entirely due to direct viral DNA genomic integration. The most aggressive oncogenic phenotype emerged within the Hepatitis Delta virus superinfection subgroup, which registered the highest rates of multifocal lesions and early macrovascular invasion. These findings dictate an immediate shift away from universal screening paradigms. Recognizing the virus-specific phenotypic expressions of hepatocellular carcinoma mandates the deployment of tailored, pathogen-specific surveillance protocols, directly improving early detection metrics and expanding the temporal window for curative surgical or ablative interventions.

PDF

References

1. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73(1):4-13.

2. Nakamura M, Kanda T, Sasaki R, et al. Genomic Integration of Hepatitis B Virus DNA and its Role in Early Hepatocarcinogenesis. Int J Mol Sci. 2023;24(8):7215.

3. Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2021;380(15):1450-1462.

4. Chen Y, Wang X, Zhang J, Li Y. Divergent Evolutionary Trajectories of Hepatitis B and C Virus-Induced Hepatocellular Carcinoma. J Hepatol. 2022;76(3):612-624.

5. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2020;69(1):182-236.

6. Russo FP, Zanetto A, Campigotto M, et al. The Mediterranean Oncology Group Analysis: Phenotypic Expressions of HCV-Related Malignancies. Liver Int. 2021;41(5):1021-1033.

7. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and early predictors of outcome. Gut. 2020;57(1):18-26.

8. Wedemeyer H, Yurdaydın C, Hardtke S, et al. Hepatitis delta virus infection: molecular mechanisms and clinical manifestation of a highly aggressive oncogenic driver. Nat Rev Gastroenterol Hepatol. 2022;19(2):120-132.

9. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.

10. D'souza S, Lau K, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol. 2020;26(38):5759-5783.

11. Kim DW, Kim J, Kim YJ, et al. Distinctive Clinical Features and Outcomes of Hepatitis B Virus and Hepatitis Delta Virus Co-infected Patients with Hepatocellular Carcinoma. Ann Surg Oncol. 2023;30(4):2145-2154.

12. Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33(2):e00046-19.

13. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology. 2021;43(6):1303-1310.

14. Turati F, Talamini R, Pelucchi C, et al. Metabolic syndrome and hepatocellular carcinoma risk: A comprehensive review of virological interactions. Cancer Epidemiol Biomarkers Prev. 2022;31(10):1854-1862.

15. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2020;16(10):589-604.